Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 8, 2003, Pages 3374-3381

  Bakalash, Sharon ^a   Kessler, Anat ^b   Mizrahi, Tal ^a   Nussenblatt, Robert ^c   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PEPTIDE A91; PEPTIDE AS472; PEPTIDE R16; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARGON PLASMA COAGULATION; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; GLAUCOMA; IMMUNE RESPONSE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; UVEITIS; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; CELL SURVIVAL; CYTOPROTECTION; DISEASE MODELS, ANIMAL; EYE PROTEINS; GLAUCOMA; IMMUNODOMINANT EPITOPES; INTRAOCULAR PRESSURE; MALE; METHYLPREDNISOLONE; MYELIN BASIC PROTEINS; OCULAR HYPERTENSION; OLIGOPEPTIDES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; RETINOL-BINDING PROTEINS; UVEITIS; VACCINATION; VACCINES, SYNTHETIC;

EID: 0042844813     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0080     Document Type: Article

References (47)

1. Schwartz M. Autoimmune involvement in CNS trauma is beneficial if well controlled. Prog Brain Res. 2000;128:259-263.
2. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA. 2001;98:3398-3403.
3. Kipnis J, Yoles E, Schori H, et al. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci. 2001;21:4564-4571.
4. Yoles E, Schwartz M. Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol. 1998;153:1-7.
5. Schwartz M, Kipnis J. Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift. The Neuroscientist. 2002;8:405-413.
6. Kipnis J, Mizrahi T, Hauben E, et al. Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci USA. 2002;99:15620-15625.
7. Schwartz M. T cell mediated neuroprotection is a physiological response to central nervous system insults. J Mol Med. 2001;78:594-597.
8. Hauben E, Ibarra A, Mizrahi T, et al. Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens. Proc Natl Acad Sci USA. 2001;98:15173-15178.
9. Mizrahi T, Hauben E, Schwartz M. The tissue-specific self-pathogen is the protective self-antigen: The case of uveitis. J Immunol. 2002;169:5971-5977.
10. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) as a treatment for autoimmune diseases and a vaccine for protective autoimmunity after CNS injury. Trends Mol Med. 2002;8:319-323.
11. Nevo U, Kipnis J, Golding I, et al. Autoimmunity as a special case of immunity: removing threats from within. Trends Mol Med. 2003;9:88-93.
12. Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA. 2000;97:7446-7451.
13. Hafler DA, Weiner HL. Antigen specific therapies for the treatment of autoimmune diseases. Agents Actions Suppl. 1995;47:59-77.
14. Hauben E, Butovsky O, Nevo U, et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci. 2000;20:6421-6430.
15. Fisher J, Levkovitch-Verbin H, Schori H, et al. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J Neurosci. 2001;21:136-142.
16. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci. 2002;43:2648-2653.
17. Jia L, Cepurna WO, Johnson EC, Morrison JC. Patterns of intraocular pressure elevation after aqueous humor outflow obstruction in rats. Invest Ophthalmol Vis Sci. 2000;41:1380-1385.
18. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci. 2002;43:402-410.
19. Jia L, Cepurna WO, Johnson EC, Morrison JC. Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction. Invest Ophthalmol Vis Sci. 2000;41:3415-3419.
20. Yoles E, Hauben E, Palgi O, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci. 2001;21:3740-3748.
21. Brocke S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996;379:343-346.
22. Hauben E, Agranov E, Gothilf A, et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest. 2001; 108:591-599.
23. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 2000;403:434-439.
24. Merkler D, Metz GA, Raineteau O, et al. Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci. 2001;21:3665-3673.
25. Huber AB, Schwab ME. Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol Chem. 2000;381:407-419.
26. Steinsapir KD, Goldberg RA, Sinha S, Hovda DA. Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci. 2000;17:157-163.
27. Derendorf H, Mollmann H, Rohdewald P, Rehder J, Schmidt EW. Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther. 1985;37:502-507.
28. Dua HS, Abrams MS, Barrett JA, Donoso LA. The effect of retinal autoantigens and their peptides on the inhibition of experimental autoimmune uveitis. Eye. 1992;6:447-452.
29. Wacker WB, Kalsow CM. Autoimmune uveo-retinitis in the rat sensitized with retina photoreceptor cell antigen. Int Arch Allergy Appl Immunol. 1973;45:582-592.
30. Gregerson DS, Obritsch WF, Fling SP, Cameron JD. S-antigen-specific rat T cell lines recognize peptide fragments of S- antigen and mediate experimental autoimmune uveoretinitis and pinealitis. J Immunol. 1986;136:2875-2882.
31. Caspi RR. Immune mechanisms in uveitis. Springer Semin Immunopathol. 1999;21:113-124.
32. Schori H, Yoles E, Schwartz M. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J Neuroimmunol. 2001;119:199-204.
33. Schori H, Lantner F, Shachar I, Schwartz M. Severe immunodeficiency has opposite effects on neuronal survival in glutamate-susceptible and -resistant mice: adverse effect of B cells. J Immunol. 2002;169:2861-2865.
34. Moalem G, Leibowitz-Amit R, Yoles E, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5:49-55.
35. Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma. 1998;7:165-169.
36. Quigley HA. Neuronal death in glaucoma. Prog Retinal Eye Res. 1999;18:39-57.
37. Doekes G, van der Gaag R, Rothova A, et al. Humoral and cellular immune responsiveness to human S-antigen in uveitis. Curr Eye Res. 1987;6:909-919.
38. Wacker WB. Experimental allergic uveitis. Studies on characterization and isolation of the pathogenic retina antigen Int Arch Allergy Appl Immunol. 1973;45:639-656.
39. Wacker WB. Proctor Lecture. Experimental allergic uveitis Investigations of retinal autoimmunity and the immunopathologic responses evoked. Invest Ophthalmol Vis Sci. 1991;32:3119-3128.
40. Kipnis J, Mizrahi T, Yoles E, Ben-Nun A, Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J Neuroimmunol. 2002;130:78-85.
41. Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J. 2002;16:1304-1306.
42. Moalem G, Gdalyahu A, Shani Y, et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun. 2000;15:331-345.
43. Kerchensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189:865-870.
44. Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy? Curr Opin Ophthalmol. 2000;11:145-150.
45. Steiner I, Brenner T, Mizrachi-Kol R, Abramsky O. Development of experimental allergic encephalomyelitis during steroid administration: outcome of neurological immune-mediated disorders under immunosuppressive therapy. Isr J Med Sci. 1991;27:365-368.
46. Schmidt J, Gold R, Schonrock L, et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methyl-prednisolone pulse therapy. Brain. 2000;123:1431-1441.
47. Schwartz M, Yoles E. Self-destructive and self-protective processes in the damaged optic nerve: implications for glaucoma. Invest Ophthalmol Vis Sci. 2000;41:349-351.